BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Pfizer

Here's What Vaccine CEOs Have to Say About the Omicron Variant

Advisorshares Hotel ETF

Choice Hotels Int.

Hyatt Hotels

Hilton Worldwide Holdings

InterContinental Hotels Group

Marriott

SPDR S&P 500 ETF Trust

Wyndham Hotels & Resorts Inc

Hotel stocks are up across the board after President Joe Biden reiterated his message that the U.S. won't face another lockdown. The post Hotel Stocks: Why MAR, H, HLT, WH, CHH and IHG Are Booking Gains Today appeared first on InvestorPlace.

Hotel Stocks: Why MAR, H, HLT, WH, CHH and IHG Are Booking Gains Today

The European Union-wide rollout of Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine for five- to 11-year-old children will begin December 13, one week earlier than previously planned, Germany's health ministry said. "Given the current pandemic situation, this is good news for parents and children.

Europe To Start Deliveries Of Pfizer/BioNTech COVID-19 Shot For Children One Week Ahead Of Plan: Reuters

The British government has agreed on deals to buy 114 million more Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) COVID-19 vaccine shots. The new contracts with Pfizer/BioNTech and Moderna were accelerated in light of the emergence of the new Omicron variant.

Britain Agrees To New Deals For 114M Additional Moderna, Pfizer/BioNTech COVID-19 Vaccine Doses

The emergence of the new Omicron COVID strain is concerning - but has boosted the share prices of Moderna and BioNTech. Omicron may not respond to current vaccines developed by these pioneering companies due to the number of spike protein mutations.

Buy BioNTech, Sell Moderna On Omicron Variant Price Volatility

The emergence of a worrisome coronavirus variant is benefiting shares of vaccine makers Moderna Inc, BioNTech and Pfizer as investors search for winning bets in markets roiled by uncertainty in recent days.

Analysis: As Omicron plays havoc with markets, shares of vaccine makers surge

The omicron variant of the coronavirus could lead to more infections among vaccinated people but they will most likely remain protected from a severe course of illness, according to the inventor of one of the first Covid-19 vaccines.

The Wall Street Journal: Omicron variant unlikely to cause severe illness in vaccinated people, BioNTech founder says

Pfizer continues to build upon its position as the undisputed leader in the mission to combat COVID-19.

Is This Leading COVID Stock a Buy Right Now?

The FDA could authorize COVID-19 boosters from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for use in 16 and 17-year olds as soon as next week, reports Wall Street Journal, citing a person familiar with the planning. The agency is planning to rapidly take action on a request by the companies to authorize boosters for 16 and 17 year-olds.

FDA May Authorize Pfizer-BioNTech COVID-19 Booster Shots For Age 16-17 Next Week: WSJ

The company is getting a quick start on heading off a potential major global health threat.

Why BioNTech Is Beating the Market Today

Novavax

Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.

Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?

Johnson & Johnson

The omicron variant dealt the stock market a blow, but these vaccine stocks promise investors a way to cash in while combatting Covid-19. The post 5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market appeared first on InvestorPlace.

5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market

AstraZeneca

Fears about the Omicron variant of Covid-19 rattled the world's financial markets Friday and early Monday morning. But shares of the major coronavirus vaccine makers were getting a boost from the latest pandemic jitters.

Covid vaccine makers' stocks soar on Omicron variant concerns

The German biotech, which makes COVID-19 vaccines with Pfizer, said Monday it doesn't want to "waste any time" and is working on an "adapted" vaccine.

BioNTech has already started developing a new Omicron version of its COVID-19 vaccine

Clorox

Kroger

Lakeland Industries

Zoom Video

Stocks sold off sharply on Black Friday with concerns over a new Covid variant adding to macro uncertainties. The potential for new travel restrictions or return of social distancing measures represents a deeply bearish development for the market with risks tilted to the downside.

Specter Of New Covid Lockdowns Can Lift These 5 Stocks

Pfizer and BioNTech said they expect more data from lab tests in two weeks at the latest.

Pfizer-BioNTech investigating new Covid variant, while J&J say they are testing their vaccine against it

DocuSign

Peloton

Little is known about the new COVID strain emerging in Africa. That hasn't stopped traders from betting big on lockdowns and a return to telework.

Forget reopening. The new COVID variant has 'stay-at-home' stocks rebounding.

The stock prices of vaccine makers Moderna and Pfizer surged Friday along with stay-at-home stocks like Zoom Video and Peloton.

Pandemic-related stocks from Zoom to Moderna jump as new coronavirus variant raises alarms and triggers lockdowns

The B.1.1.529 variant has been detected in South Africa, Botswana, Hong Kong, and Israel, and is spreading rapidly.

BioNTech says it will know in 2 weeks whether the COVID-19 vaccine it developed with Pfizer works against the new variant rapidly spreading in southern Africa

Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe

Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11

The stock price of BioNTech SE (NASDAQ: BNTX) increased by over 7% pre-market today. This is why it happened.

BioNTech (BNTX): Why The Price Jumped Today

BioNTech (BNTX) Stock: Why The Price Jumped Today

The European Medicines Agency's (EMA) human medicines committee (CHMP) recommended using Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX)'s COVID-19 vaccine, Comirnaty, for children between 5 to 11. Pfizer-BioNTech's vaccine will be given in two 10-microgram doses three weeks apart as an injection in the upper arm, per the EMA recommendation.

Europe's CHMP Backs Pfizer/BioNTech's COVID-19 Shot For Kids Aged 5-11 Years

NEW YORK and MAINZ, Germany, November 25 , 2021— Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies' COVID-19 vaccine COMIRNATY® in children 5 to under 12 years of age. The European Commission (EC) will review the CHMP recommendation and is expected to make a final decision on a variation to the Conditional Marketing Authorization in the near future. If the EC grants the variation regarding a vaccination in this age group, the decision will be immediately applicable to all 27 EU member states. If approved, COMIRNATY will be the first COVID-19 vaccine authorized in the European Union for individuals 5 to under 12 years of age.

News for BioNTech SE Stock (BNTX)